This drug candidate is intended for the prophylactic protection against food allergens and is currently in Phase IIb clinical development. Pursuant to the agreement, GSK will obtain the global rights (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop and commercialize ozureprubart. Concurrently, GSK will assume the responsibility for future success-based milestone and royalty payments owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd.

IgE is a clinically validated target and is the only approved systemic therapy shown to protect patients from a harmful allergic and inflammatory immune response. Around 94% of severe food allergies are caused by IgE-mediated reactions.

C-CAR031 is an autologous, Glypican-3 (GPC3)-targeting chimeric antigen receptor T-cell (CAR-T) therapy. Based on AstraZeneca's novel GPC3-targeting CAR-T candidate (AZD5851), it is designed using AstraZeneca's dominant negative transforming growth factor-beta receptor II (dnTGFβRII) armoring platform and is manufactured by AbelZeta in China. It is currently being investigated for the treatment of hepatocellular carcinoma (HCC) and other solid tumors.

At JPM 2026, 24 Chinese innovative biopharmaceutical companies presented in the main conference and Asia-Pacific sessions, while an even greater number completed significant licensing deals with multinational corporations during the event. In key focus areas at JPM 2026, such as antibody-drug conjugates (ADCs), metabolic diseases, and cell and gene therapies, Chinese innovative drugs have become an indispensable source of value.

Given the complexity of the CNS and the challenges in drug development, there remains a substantial unmet clinical need for many CNS diseases. With continuous advancements in sophisticated research instruments, fundamental research in the CNS field has reached a tipping point.

The asset has been developed internally by PepLib to date. Through this transaction, Novartis, anexperienced global leader in RLTs, will advance the program to its next stage of development.

Reportedly, traditional ADC drugs still have several limitations. First, for an ADC to exert its therapeutic effect, the antibody component must be internalized by cells, which restricts the selection of suitable antibodies. Furthermore, the release of the ADC's payload involves multiple steps, such as tumor cell endocytosis and lysosomal degradation, each of which may lead to treatment failure or drug resistance.

On December 31, 2025, Zelgen Biopharmaceuticals announced that it has entered into a strategic collaboration and option agreement with an affiliate of AbbVie. for the global development and commercialization of ZG006 (Alveltamig). The candidate, ZG006, is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for the treatment of small cell lung cancer and other DLL3-expressing malignant tumors.

Recently, disease control and prevention centers across China have rolled out subsidized vaccination initiatives for herpes zoster. Two approved herpes zoster vaccines in China have undergone significant price reductions: the second dose of GSK's imported recombinant herpes zoster vaccine (brand name: Shingrix®) is now offered free of charge, while the domestic herpes zoster live attenuated vaccine produced by BCHT (brand name: Gan Wei) is available at a discount of 30% to 80%.

Looking back to April 17, 2025, Sanofi had previously secured global exclusive rights to two bispecific antibodies from Helixon—HXN-1002 (targeting α4β7/TL1A) and HXN-1003 (targeting TL1A/IL-23)—with an upfront payment of $125 million and a total potential deal value of up to $1.845 billion.

On December 22, AstraZeneca's Benralizumab Injection (brand name: Fasenra®, generic name: Benralizumab Injection) received approval from the China National Medical Products Administration (NMPA) for a new indication, for the treatment of adult eosinophilic granulomatosis with polyangiitis (EGPA).

ZG006 is a novel trispecific T-cell engager targeting two distinct DLL3 epitopes and CD3. It represents the world's first DLL3-targeting trispecific antibody (CD3/DLL3/DLL3) with best-in-class potential. Currently, it is in late-stage clinical development for the treatment of small cell lung cancer (Phase III) and other DLL3-expressing malignancies.

This trend not only marks the transition of bispecific antibody technology from a niche field to a mainstream focus but also signals its potential to replace traditional monoclonal antibodies and antibody-drug conjugates as the cornerstone of next-generation biopharmaceutical development.

On December 12, Eli Lilly released updated results from the Phase 3 EMBER-3 clinical trial of imlunestrant, an oral estrogen receptor antagonist. The study enrolled patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced or metastatic breast cancer (MBC) who had previously received treatment with an aromatase inhibitor (AI) with or without a CDK4/6 inhibitor and experienced disease progression. Compared with endocrine therapy, imlunestrant monotherapy showed a clinically meaningful 38% reduction in the risk of disease progression or death in patients harboring ESR1 mutations.

Leveraging its leading expertise in small-molecule technology, Jacobio has become one of the companies with the most advanced clinical progress in this field. This collaboration extends beyond a traditional asset licensing agreement to include co-development within the Chinese market, marking the entry into a new phase of partnership models between Chinese innovative drug companies and global pharmaceutical giants.

Under the terms of the agreement, Jacobio will receive an upfront payment of US$100 million, and is eligible for additional development and commercial milestone payments of up to US$1.915 billion, as well as tiered royalties on net sales achieved outside of China. AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 outside of China.

On December 7, Eli Lilly announced new results from the Phase III BRUIN CLL-314 clinical trial. This study aimed to evaluate the efficacy of the non-covalent (reversible) BTK inhibitor Jaypirca® (pirtobrutinib) compared to the covalent BTK inhibitor Imbruvica® (ibrutinib) in patients with treatment-naïve or previously untreated (without prior BTK inhibitor therapy) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Aficamten tablets are a potential "best-in-class" therapeutic for hypertrophic cardiomyopathy. This approval marks Aficamten as an innovative drug achieving its "global first launch" in China, with authorization occurring earlier than in other countries and regions worldwide, including the United States and the European Union.

The collaboration will focus on "next-generation multi-specific antibodies"—an advanced class of antibody therapies designed to enhance therapeutic efficacy and reduce toxicity by simultaneously targeting multiple signaling pathways.

Nerandomilast is an oral, selective phosphodiesterase 4B (PDE4B) inhibitor, now approved in China for the treatment of both idiopathic pulmonary fibrosis (IPF) and PPF in adults. In the United States, the drug has been granted Priority Review and Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and is already approved for the treatment of IPF. Currently, the FDA is conducting a Priority Review of nerandomilast for the treatment of adult PPF.